A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
About the study
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Has a confirmed diagnosis of endogenous Cushing syndrome
- Meets at least one of the following criteria:
- Has Type 2 diabetes mellitus
- Has impaired glucose tolerance
- Has hypertension
EXCLUSION CRITERIA
Exclusion Criteria:
- Has non-endogenous source of hypercortisolemia
- Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
- Has poorly controlled hypertension
- Has poorly controlled diabetes mellitus
- Has severe renal insufficiency
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Cushing Syndrome
Age (in years)
18 - 80
Phase
Phase 3
Participants needed
152
Est. Completion Date
Mar 31, 2024
Treatment type
Interventional
Sponsor
Corcept Therapeutics
ClinicalTrials.gov identifier
NCT03697109
Study number
CORT125134-455
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?